These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

342 related items for PubMed ID: 10223235

  • 1. Type I collagen metabolites as tumor markers in patients with lung carcinoma.
    Kobayashi T, Gabazza EC, Taguchi O, Risteli J, Risteli L, Kobayashi H, Yasui H, Yuda H, Sakai T, Kaneda M, Adachi Y.
    Cancer; 1999 May 01; 85(9):1951-7. PubMed ID: 10223235
    [Abstract] [Full Text] [Related]

  • 2. Serum concentrations of type I collagen carboxyterminal telopeptide (ICTP) and type I procollagen carboxy-and aminoterminal propeptides (PICP, PINP) as markers of metastatic bone disease in breast cancer.
    Tähtelä R, Thölix E.
    Anticancer Res; 1996 May 01; 16(4B):2289-93. PubMed ID: 8694558
    [Abstract] [Full Text] [Related]

  • 3. Serum cross-linked carboxyterminal telopeptide of type I collagen (ICTP) as a prognostic tumor marker in patients with esophageal squamous cell carcinoma.
    Nabeya Y, Shimada H, Okazumi S, Matsubara H, Gunji Y, Suzuki T, Ochiai T.
    Cancer; 2002 Feb 15; 94(4):940-9. PubMed ID: 11920462
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Pyridinoline cross-linked carboxyterminal telopeptide of type I collagen as a useful marker for monitoring metastatic bone activity in men with prostate cancer.
    Noguchi M, Noda S.
    J Urol; 2001 Sep 15; 166(3):1106-10. PubMed ID: 11490307
    [Abstract] [Full Text] [Related]

  • 7. Comparison of bone scintigraphy with bone markers in the diagnosis of bone metastasis in lung carcinoma patients.
    Ebert W, Muley T, Herb KP, Schmidt-Gayk H.
    Anticancer Res; 2004 Sep 15; 24(5B):3193-201. PubMed ID: 15510610
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Serum type I collagen degradation markers, ICTP and CrossLaps, are factors for poor survival in lung cancer.
    Ylisirniö S, Sassi ML, Risteli J, Turpeenniemi-Hujanen T, Jukkola A.
    Anticancer Res; 1999 Sep 15; 19(6C):5577-81. PubMed ID: 10697621
    [Abstract] [Full Text] [Related]

  • 10. The amino-terminal propeptide (PINP) of type I collagen is a clinically valid indicator of bone turnover and extent of metastatic spread in osseous metastatic breast cancer.
    Pollmann D, Siepmann S, Geppert R, Wernecke KD, Possinger K, Lüftner D.
    Anticancer Res; 2007 Sep 15; 27(4A):1853-62. PubMed ID: 17649784
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Clinical usefulness of serum pyridinoline cross-linked carboxyterminal telopeptide of type I collagen for diagnosis of bone metastases in patients with primary lung cancer.
    Yokoyama T, Yamamoto M, Shima K, Suzuki K, Sako C, Ito G, Kume M, Maeda M.
    Respirology; 2005 Jun 15; 10(3):300-4. PubMed ID: 15955141
    [Abstract] [Full Text] [Related]

  • 16. [Measurements and clinical usefulness of carboxyterminal propeptide of type I collagen and cross-linked carboxyterminal telopeptide of type I collagen in patients with prostate cancer].
    Igawa T, Sakai H, Kanetake H, Saito Y.
    Hinyokika Kiyo; 1999 Apr 15; 45(4):235-9. PubMed ID: 10363141
    [Abstract] [Full Text] [Related]

  • 17. Serum concentration of type I collagen metabolites as a quantitative marker of bone metastases in patients with prostate carcinoma.
    Yoshida K, Sumi S, Arai K, Koga F, Umeda H, Hosoya Y, Honda M, Yano M, Moriguchi H, Kitahara S.
    Cancer; 1997 Nov 01; 80(9):1760-7. PubMed ID: 9351545
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.